Buprenorphine/naloxone - one formulation that doesn't fit all: a case report
Abstract Background Sublingual buprenorphine, approved for treatment of opioid use disorder since 2002, is most commonly available in co-formulation with naloxone. Naloxone is an opioid antagonist minimally absorbed when sublingual (SL) buprenorphine/naloxone is taken as prescribed; it is thought to...
Furkejuvvon:
| Váldodahkkit: | , , |
|---|---|
| Materiálatiipa: | Girji |
| Almmustuhtton: |
BMC,
2024-07-01T00:00:00Z.
|
| Fáttát: | |
| Liŋkkat: | Connect to this object online. |
| Fáddágilkorat: |
Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|
Interneahtta
Connect to this object online.3rd Floor Main Library
| Hildobáiki: |
A1234.567 |
|---|---|
| Njađus 1 | Oažžumis |